caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1932291119

Sonal PhatakM.D.

PRACTICEUCSDSee all providers at this practice →
EndocrinologySanta Barbara, CAI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
962
Unique beneficiaries
—
Total services
3,805
Distinct HCPCS
12
Medicare payment
$142K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 633 Endocrinology providers in CA — top quintile (cohort median 1,164).
REFERRAL NETWORK

Where Sonal Phatak's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 7 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
Sanyukta Pawar
Internal Medicine · Rocklin, CA
82302
HOOPER, MICHAEL49151
SUTTER, CHARLES39102
Victor Bonilla
Cardiology · Roseville, CA
1637
Niti Madan
Nephrology · Sacramento, CA
1442
Yunli Zheng
Internal Medicine · Roseville, CA
1267
Guadalupe Avila-Kirwan
Internal Medicine · Auburn, CA
1134
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
PRESCRIBING · PART D · 2024
Total Rx claims
1,256
Beneficiaries
—
Total drug cost
$429K
Distinct drugs
23
Brand share
36.8%
Top prescribed drugs
Levothyroxine Sodium345 claims
Alendronate Sodium144 claims
Levothyroxine Sodium108 claims
Empagliflozin63 claims
Semaglutide50 claims
QUALITY · MIPS · 2024
Final MIPS score
90.1
Quality
86.2
Cost
78.4
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.64%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.